Results 221 to 230 of about 15,564 (249)

Solution behaviour of Human Serum Albumin and GLP-1variants [PDF]

, 2016
Sønderby, Pernille
core  

Management of Myasthenic Crisis and Emerging Roles of Molecularly Targeted Therapies: A Narrative Review. [PDF]

Neurol Int
Takahashi S, Kinno R.
europepmc   +1 more source

FCRN MEDIATED MUCOSAL IMMUNITY AND SUBUNIT VACCINE DELIVERY

, 2009
Lilin Ye
openalex   +1 more source

Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network. [PDF]

Front Immunol
Wang L, Chen J, Li H, Wang L, Liu F, Jiang X.   +5 more
europepmc   +1 more source

Efgartigimod as Rescue Therapy for PD-1 Inhibitor-Associated Myasthenia Gravis, Myocarditis, and Myositis (MMM) Syndrome: A 2-Case Report and Literature Review. [PDF]

Am J Case Rep
Liu ZH, Duan LM, Fang XZ, Jiang W, Sun SW, Shang Y, Huang CL, Yuan Y.   +7 more
europepmc   +1 more source

What has changed in thyroid eye disease in the last five years (2020-2025). [PDF]

Eur Thyroid J
Salvi M.
europepmc   +1 more source

Does the Chimerization Process Affect the Immunochemical Properties of WNV-Neutralizing Antibody 900? [PDF]

Int J Mol Sci
Isaeva AA, Nesmeyanova VS, Shanshin DV, Ushkalenko ND, Volosnikova EA, Esina TI, Protopopova EV, Svyatchenko VA, Loktev VB, Olkin SE, Danilenko ED, Kazachinskaia EI, Shcherbakov DN.   +12 more
europepmc   +1 more source

Study of the level of FcRn expression on the antitumor response : impact on Natural Killer cells (NK)

, 2018
Diana Cadena Castaneda
openalex   +1 more source

Preclinical evaluation of an antibody-based companion diagnostic for CD44v6 expressing cancer. [PDF]

Nucl Med Commun
Oroujeni M, Selvaraju RK, Persson H, Dahllund L, Frejd FY, Mortensen ACL.   +5 more
europepmc   +1 more source

Efgartigimod as Fast-Acting Rescue Therapy in Very Late-Onset Myasthenia Gravis. [PDF]

Neurol Ther
Rini N, D'Amico F, Portera V, Brighina F, Di Stefano V.   +4 more
europepmc   +1 more source